Fluidigm (FLDM) Sees Large Volume Increase

Fluidigm Co. (NASDAQ:FLDM) saw unusually-strong trading volume on Friday . Approximately 857,690 shares traded hands during mid-day trading, an increase of 350% from the previous session’s volume of 190,498 shares.The stock last traded at $7.35 and had previously closed at $7.18.

A number of research analysts recently commented on FLDM shares. Zacks Investment Research cut Fluidigm from a “hold” rating to a “sell” rating in a report on Monday, August 27th. BidaskClub raised Fluidigm from a “hold” rating to a “buy” rating in a report on Wednesday, September 12th. Finally, Piper Jaffray Companies raised Fluidigm from a “neutral” rating to an “overweight” rating in a report on Friday.

The company has a quick ratio of 1.64, a current ratio of 2.05 and a debt-to-equity ratio of 4.79. The firm has a market capitalization of $290.59 million, a P/E ratio of -6.18 and a beta of 3.44.

Fluidigm (NASDAQ:FLDM) last posted its quarterly earnings results on Thursday, November 1st. The medical research company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.20). Fluidigm had a negative return on equity of 104.75% and a negative net margin of 53.65%. The business had revenue of $28.96 million during the quarter, compared to analysts’ expectations of $27.50 million. On average, analysts anticipate that Fluidigm Co. will post -0.99 EPS for the current year.

In other Fluidigm news, insider Levin Capital Strategies, L.P. purchased 9,962 shares of the stock in a transaction that occurred on Friday, October 26th. The shares were bought at an average cost of $7.20 per share, with a total value of $71,726.40. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Over the last three months, insiders purchased 98,951 shares of company stock worth $715,224. 2.20% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN raised its holdings in shares of Fluidigm by 64.8% during the 1st quarter. Wells Fargo & Company MN now owns 28,945 shares of the medical research company’s stock worth $169,000 after acquiring an additional 11,377 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Fluidigm by 47.9% during the 1st quarter. New York State Common Retirement Fund now owns 38,900 shares of the medical research company’s stock worth $227,000 after acquiring an additional 12,600 shares in the last quarter. Perkins Capital Management Inc. raised its holdings in shares of Fluidigm by 9.9% during the 2nd quarter. Perkins Capital Management Inc. now owns 169,000 shares of the medical research company’s stock worth $1,007,000 after acquiring an additional 15,250 shares in the last quarter. LMR Partners LLP purchased a new stake in shares of Fluidigm during the 2nd quarter worth approximately $144,000. Finally, BlackRock Inc. raised its holdings in shares of Fluidigm by 1.3% during the 1st quarter. BlackRock Inc. now owns 2,212,763 shares of the medical research company’s stock worth $12,923,000 after acquiring an additional 27,881 shares in the last quarter. 96.87% of the stock is currently owned by institutional investors and hedge funds.

Fluidigm Company Profile (NASDAQ:FLDM)

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Further Reading: What are the economic characteristics of a bear market?

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply